secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0000950170-24-095526
Event type: leadership
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara CEO Pascal Touchon to step down, succeeded by Cokey Nguyen; Q2 net loss narrows to $19M
--------------------------------------------------------------------------------

- Pascal Touchon steps down as CEO effective Sep 9, 2024, becomes Chairman; Cokey Nguyen promoted to President and CEO.
- Q2 2024 net loss of $19.0M ($3.10 per share) vs $71.1M loss in Q2 2023; revenue of $28.6M (up from $1.0M).
- Tab-cel BLA accepted with Priority Review, PDUFA target Jan 15, 2025; $20M milestone received from Pierre Fabre.
- Cash, equivalents, short-term investments $35.3M; with milestones and inventory purchase total liquidity $73.2M; cash runway into 2027.
- ATA3219 NHL study enrolling with initial data expected Q1 2025; LN study initiation Q4 2024, data mid-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024095526/0000950170-24-095526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000095017024095526/atra-20240810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-095526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer